Leap Therapeutics, Inc.
LPTX
$0.369
-$0.0053-1.42%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.85M | 12.97M | 13.36M | 13.55M | 13.81M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 70.06M | 68.78M | 64.70M | 58.07M | 85.94M |
| Operating Income | -70.06M | -68.78M | -64.70M | -58.07M | -85.94M |
| Income Before Tax | -67.20M | -64.12M | -60.34M | -53.37M | -81.41M |
| Income Tax Expenses | 585.00K | 708.00K | -- | -- | -- |
| Earnings from Continuing Operations | -67.79 | -64.82 | -60.34 | -53.37 | -81.41 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -67.79M | -64.82M | -60.34M | -53.37M | -81.41M |
| EBIT | -70.06M | -68.78M | -64.70M | -58.07M | -85.94M |
| EBITDA | -70.05M | -68.77M | -64.69M | -58.05M | -85.93M |
| EPS Basic | -1.85 | -1.94 | -2.00 | -2.39 | -5.12 |
| Normalized Basic EPS | -1.38 | -1.19 | -1.25 | -1.49 | -3.20 |
| EPS Diluted | -1.85 | -1.94 | -2.00 | -2.39 | -5.12 |
| Normalized Diluted EPS | -1.38 | -1.19 | -1.25 | -1.49 | -3.20 |
| Average Basic Shares Outstanding | 148.60M | 134.33M | 120.11M | 95.70M | 81.62M |
| Average Diluted Shares Outstanding | 148.60M | 134.33M | 120.11M | 95.70M | 81.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |